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Abstract
Background: Although La Crosse virus (LACV) is one of the most common causes of pediatric arboviral infections in the
United States, little has been done to assess its geographic distribution, identify areas of higher risk of disease, and to
provide a national picture of its clinical presentation. Therefore, the objective of this study was to investigate the
geographic distribution of LACV infections reported in the United States, to identify hot-spots of infection, and to present its
clinical picture.
Methods and Findings: Descriptive and cluster analyses were performed on probable and confirmed cases of LACV
infections reported to the Centers for Disease Control and Prevention from 2003–2007. A total of 282 patients had reported
confirmed LACV infections during the study period. Of these cases the majority (81 percent) presented during the summer,
occurred in children 15 years and younger (83.3 percent), and were found in male children (64.9 percent). Clinically, the
infections presented as meningioencephalitis (56.3 percent), encephalitis (20.7 percent), meningitis (17.2 percent), or
uncomplicated fever (5 percent). Deaths occurred in 1.9 percent of confirmed cases, and in 8.6 percent of patients suffering
from encephalitis. The majority of these deaths were in patients 15 years and younger. The county-level incidence risk
among counties (n=136) reporting both probable and confirmed cases for children 15 years and younger (n=355) ranged
from 0.2 to 228.7 per 100,000 persons. The southern United States experienced a significantly higher (p,0.05) incidence risk
during the months of June, July, August, and October then the northern United States. There was significant (p,0.05)
clustering of high risk in several geographic regions with three deaths attributed to complications from LAC encephalitis
occurring in two of these hot-spots of infections.
Conclusions: Both the incidence risk and case fatality rates were found to be higher than previously reported. We detected
clustering in four geographic regions, a shift from the prior geographic distributions, and developed maps identifying high-
risk areas. These findings are useful for raising awareness among health care providers regarding areas at a high risk of
infections and for guiding targeted multifaceted interventions by public health officials.
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Introduction
La Crosse virus (LACV) is a member of the genus Orthobunya-
virus, family Bunyaviridae, and is the causative agent of LACV
infections. LACV was first isolated in 1964 [1], and has become
one of most common causes of pediatric arboviral infections in the
United States [2,3]. The majority of LACV infections are
transmitted to humans through the bite of the primary vector,
the eastern tree-hole mosquito, Aedes triseriatus [4,5]. The virus is
maintained in nature through a vertical and horizontal transmis-
sion cycle involving Ae. triseriatus [6,7,8] and the primary
amplification hosts: the eastern chipmunk, Tamias striatus, the gray
squirrel, Sciurus carolinensis, and the fox squirrel Sciurus niger [9,10].
LACV has traditionally been associated with forested areas in
the upper-midwestern United States [11], but more recently as an
emerging disease in the Appalachian region of the United States
[12,13,14]. Unlike West Nile virus (WNV) infections that are more
severe in the adults [15], the majority of severe LACV cases occur
in children 15 years and younger [11,16,17,18], with an average of
79 nationally reported cases per year since 1964, though pockets of
higher infection risk have been reported [19]. The incidence risk
in children 15 years and younger was believed to be 20–30 cases
per 100,000, with a case fatality rate of less than 1 percent
[13,16,17]. However, the true incidence of LACV infections are
unknown as cases are typically under diagnosed, under-reported,
and some are asymptomatic [18,19,20,21]. In this study, we
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6145examined probable and confirmed cases of LACV infections from
2003–2007, to determine incidence risk, case fatality rates, and to
assess the current spatial patterns of disease risk so as to identify
those areas of highest risk for the implementation of future disease
control strategies.
Methods
Study area
Our study area encompassed the eastern United States, the
geographic region that includes the majority of previously reported
LACV infections and the range of the primary vector, Ae. triseriatus
[2,16,18,22]. County level incidence risks were calculated and
spatial analyses performed on 24 states in the study area.
Seventeen of the 24 states reported probable and confirmed cases
of LACV infections in children 15 years and younger (Table 1).
The following states were part of the study area but did not report
any LACV infections in children 15 years and younger during the
study period: Arkansas, Delaware, Florida, Maryland, Missouri,
New Jersey, and Pennsylvania. All of these states have reported
LACV infections in the past.
Disease data
This study was conducted for all states reporting probable and
confirmed cases of LACV infections in the United States, 2003–
2007, through the ArboNET surveillance system [23]. The
ArboNET surveillance system was established by the Centers for
Disease Control and Prevention in 2000 to monitor the spread of
West Nile virus in the United States. In 2003, the system was
expanded to collect data on other arboviral diseases. Through
ArboNET, participating health departments report human cases
of arboviral disease. The ArboNET system was queried by the
Centers for Disease Control and Prevention to search for all
LACV infections.
Personal identifiers of patients were deleted before database
construction. Clinical and epidemiological LACV data for 151
probable and 275 confirmed cases of LACV infections reported
during this time period were provided by the Centers for Disease
Control and Prevention. Cases that acquired infection outside of
the county/state were excluded from spatial analyses (n=10). This
research was deemed exempt from review and certification by the
University of Tennessee’s Institutional Review Board following
review by the Department of Entomology and Plant Pathology’s
Departmental Review Committee under the University of
Tennessee’s guidelines for research involving human subjects.
Case definition
Confirmed cases of LACV infections are required to meet both
the clinical and laboratory requirements set by the Centers for
Disease Controls and Prevention’s case definition for neuroinva-
sive domestic arboviral diseases [24]. This definition is reprinted
below:
In the absence of a more likely clinical explanation as
documented by a physician, confirmed cases must meet all
of the following criteria:
Clinical Criteria. 1) Fever, AND
2) Acutely altered mental status, or other acute signs of
central or peripheral neurologic dysfunction, or pleocytosis
Table 1. Non-Imported Probable and Confirmed Cases and Incidence Risk*of La Crosse Virus Infections in Children 15 Years and
Younger Reported in the eastern United States, 2003–2007, by State.
State
Reported
Cases
Percentage of
Reported Cases
Incidence Risk
by State
Range of Incidence Risk Among
Counties Reporting Cases
West Virginia 83 23.4 57.8 7.5–228.7
Ohio 73 20.6 5.0 0.3–37.1
North Carolina 66 18.6 21.0 0.5–206.7
Tennessee 50 14.1 18.4 3.6–166.6
Wisconsin 21 5.9 12.1 1.1–76.7
Illinois 18 5.1 1.3 0.2–30.8
Minnesota 9 2.5 10.6 7.3–29.8
Virginia 8 2.3 7.8 1.6–35.2
Georgia 7 2.0 2.6 0.5–129.8
Indiana 6 1.7 2.0 0.5–20.6
Louisiana 4 1.1 6.5 4.0–23.2
Iowa 3 0.8 41.4 27.7–55.1
Kentucky 3 0.8 13.5 7.7–23.6
Michigan 1 0.3 1.0 1.0
Mississippi 1 0.3 8.3 8.3
Alabama 1 0.3 0.7 0.7
South Carolina 1 0.3 1.7 1.7
Florida
{ – –––
Overall 355 100 7.2 0.3–228.7
*Incidence risk was calculated in counties reporting probable and confirmed cases of La Crosse virus infections and presented as the number of cases per 100,000
persons in children 15 years and younger, and are expressed here as a range in those states with two or more counties reporting cases.
{No incidence risk is reported for states not reporting cases 15 years and younger.
doi:10.1371/journal.pone.0006145.t001
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AND
Laboratory Criteria. 3) a four-fold or greater change in
virus-specific serum antibody titer, or isolation of virus from
or demonstration of specific viral antigen or genomic
sequences in tissue, blood, CSF, or other body fluid, or
virus-specific immunoglobulin M (IgM) antibodies demon-
strated in CSF by antibody-capture enzyme immunoassay
(EIA), or virus-specific IgM antibodies demonstrated in
serum by antibody-capture EIA and confirmed by demon-
stration of virus-specific serum immunoglobulin G (IgG)
antibodies.
Probable Case Criteria. Cases that met the clinical
definition and had stable (less than or equal to a two-fold
change) but elevated titer of virus-specific serum antibodies,
or virus-specific serum IgM antibodies detected by antibody-
capture EIA but with no available results of a confirmatory
test for virus-specific serum IgG antibodies in the same or a
later specimen, are deemed probable.
Population and geographic data
The 2005, United States Census Bureau, Estimated County
Population Dataset [25], was used to calculate the total population
and the population 15 years and younger for each county. These
populations were used to provide the denominators for calculating
incidence risk at the county level. As the United States Census
Bureau does not provide yearly population estimates that include
sex, age, and race for the county level, the 2000 United States
Census [26] was used to provide the denominators for calculating
the sex - age - and race - specific incidence risk for all counties
reporting LACV infections. Geographic boundary files were
downloaded from the United States Census, TIGER, Geodata-
base [27], and used for all cartographic displays.
Statistical and geographic analyses
Incidence risk was calculated and spatial analyses were
performed on 123 probable and 232 confirmed cases 15 years
and younger and on 151 probable and 275 confirmed cases for all
ages occurring during the study period for which county level data
were available (Table 1). Incidence risk was calculated for all
counties in the study area (n=1924) and for counties reporting
both confirmed and probable cases of LACV infections under the
age of 15 (n=136) and for all ages (n=161). Incidence risks were
expressed as the number of cases per 100,000 persons.
To determine if there was a significant difference in incidence
risk by month between states reporting cases in the northern
(n=7) and southern (n=10) regions of the study area, we
calculated the incidence risk by region and month using the both
probable and confirmed cases 15 years and younger. The northern
region was comprised of Illinois, Iowa, Indiana, Michigan,
Minnesota, Ohio, and Wisconsin. The southern region was
comprised of Alabama, Georgia, Kentucky, Louisiana, Mississippi,
North Carolina, South Carolina, Tennessee, Virginia, and West
Virginia.
All incidence risk computations and descriptive analyses were
performed using STATA 10.0 [28]. Spatial empirical Bayesian
(SEB) smoothing was used to adjust incidence risk due to spatial
autocorrelation and high variances resulting from a small number
of cases reported in some counties [29,30,31,32]. The resulting
smoothed incidence risks allow for better visualization of the
spatial patterns compared to the unsmoothed risk.
Global Moran’s I [33] and the Moran Local Indicators of
Spatial Association (LISA) were used to assess for evidence of
spatial clustering [34]. Statistical significance of both global and
local Moran’s I statistics were tested using 9999 permutations. All
spatial analyses were performed using GeoDa Version 0.95i [35],
and cartographic displays were done using ArcView GIS 9.2 [36].
Results
Descriptive analyses of cases
A total of 282 patients had confirmed LACV infections reported
to the Centers for Disease Control and Prevention (Table 2). Most
cases presented during July (24.9 percent), August (32.6 percent),
and September (23 percent). Cases ranged in age from 0.5 to 86
years, with a median age of 9 years; 83.3 percent were under the
age of 15 years, and the majority were males (64.9 percent).
The sex-specific incidence risk (per 100,000 persons) for all
counties reporting confirmed cases was 1.9 and 1.0 for males and
females, respectively. The age-specific incidence risk was 1.2 for
children under one year; 5.4 for 1–5 years; 6.8 for 6–10 years; 4.7
for 11–15 years; 0.5 for 16–20 years; and 0.2 for 21 years and
older. Blacks had the lowest race-specific incidence risk (0.3 per
100,000 persons) and American Indians had the highest (4.9 per
100,000 persons). The incidence risk for all counties reporting
probable and confirmed cases combined in children 15 years and
younger was 7.2 per 100,000 persons (mean 30.2), and 1.6 per
100,000 persons (mean 5.8) for the total population.
The incidence risk was significantly higher in the states in the
southern region than those states in the northern region for June
(p=0.0018), July (p=0.0002), August (p=0.0033), and October
(p=0.0053) (Table 3). There was no statistically significant
difference (p.0.05) in the incidence risk between the states in
the northern and southern regions for the months of March, April,
May, September, and November.
Clinically, the infections presented as meningioencephalitis
(56.3 percent), encephalitis (20.7 percent), meningitis (17.2
percent), uncomplicated fever (5 percent), or other (0.7 percent)
(Table 2). Deaths accounted for 1.9 percent of confirmed cases,
and were reported in Indiana, Michigan, Tennessee, and West
Virginia. All deaths occurred in patients suffering from LAC
encephalitis (100 percent). Of those patients presenting encepha-
litis 8.6 percent died. The majority (80 percent) of these deaths
were in patients 15 years and younger (median age 6, range 4–86)
and occurred in males (80 percent). Three deaths occurred in the
high risk clusters in West Virginia and in Tennessee.
Spatial distribution
In children 15 years and younger (probable and confirmed
combined), state-level incidence risk ranged from 0.7 to 56.4 per
100,000 persons whereas at the county-level incidence risk in
counties reporting cases, ranged from 0.2 to 228.7 per 100,000
persons (Table 1). Geographically, the highest incidence risks were
observed in western and central Illinois, northeastern Iowa, south
central Minnesota, southwestern Wisconsin, and the Appalachian
region (south central Kentucky, south central Ohio, western North
Carolina, central and eastern Tennessee, south central West
Virginia) (Figure 1). The spatial patterns are more easily
recognizable when smoothed (Figure 1b) as compared to the
unsmoothed incidence risk map (Figure 1a). The global Morans I
value for children 15 years and younger, was 0.1904 (p=0.0001)
for only confirmed cases and 0.2223 (p=0.0001) for both probable
and confirmed cases combined. Forty-seven of the counties in the
study area showed evidence of significant high incidence risk
(p,0.05) detected by LISA using confirmed cases, while 54
La Crosse Virus Infections
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detected using both probable and confirmed cases. The spatial
patterns for both confirmed cases and for probable and confirmed
cases combined were similar. Therefore, only the spatial patterns
using both the probable and confirmed cases are presented in
Figure 2. The clusters detected by using both probable and
confirmed cases combined were found in northeastern Iowa/
southwestern Wisconsin, and in south central Ohio, western North
Carolina/eastern Tennessee/northeastern Georgia, and south
central West Virginia/eastern Kentucky/northwestern Virginia
(Figure 2). The mean incidence risk for children 15 years and
younger at the county-level for those counties that were part of the
significant high clusters was 54.6 per 100,000 persons, and ranged
from 4.7 to 228.7 per 100,000 persons.
Discussion
Our study provides the first risk map of LACV infections for the
United States, and presents insights into the clinical picture of
LACV infections. We found both a higher incidence risk than
previously reported ranging up to 228.7 cases per 100,000 persons
in children 15 years and younger and a case fatality rate of 1.9
percent [5,7,8]. This study highlights the differences of the clinical
presentation of LACV infections as meningioencephalitis, enceph-
alitis, meningitis, uncomplicated fever, or other; rather than the
traditional method of reporting of infections as purely LACV
encephalitis. To our knowledge this is the first use of smoothing
techniques, the global Moran’s I, and the Moran Local Indicators
of Spatial Association (LISA) to detect spatial clustering of LACV
infections at a national level in the United States. We identified
high risk clusters in four regions of the United States. These high
Table 2. Epidemiological and Clinical Characteristics of
Confirmed and Probable La Crosse Virus Infections Reported
in the eastern United States, 2003–2007.
Variable
Total
Confirmed
(%)
Probable and
Confirmed
Cases
Combined (%)
Sex
Male 183 (64.9) 264 (60.6)
Female 99 (35.1) 172 (39.4)
Unknown – 1
Age
0.1–0.9 yr 3 (1.06) 5 (1.15)
1 yr 11 (3.9) 13 (2.98)
2–5 yr 59 (20.9) 98 (22.8)
6–10 yr 98 (34.8) 157 (26.4)
11–15 yr 64 (22.7) 87 (19.95)
16–20 yr 7 (2.5) 15 (3.44)
$21 yr 40 (14.2) 61 (13.99)
Unknown – 1
Race
White 241 (95.3) 368 (95.6)
Black or African American 9 (3.6) 11 (2.86)
American Indian or Alaska Native 3 (1.2) 4 (1.04)
Asian 0 (0) 1 (0.259)
Other 0 (0) 1 (0.259)
Unknown 29 52
Month of presentation
March 1 (0.35) 2 (0.458)
April 3 (1.06) 3 (0.686)
May 1 (0.35) 2 (0.454)
June 23 (8.2) 29 (6.64)
July 71 (24.9) 110 (25.2)
August 92 (32.6) 138 (31.6)
September 65 (23) 105 (24.0)
October 23 (8.2) 44 (10.1)
November 2 (0.71) 3 (0.686)
December 1 (0.35) 1 (0.229)
Clinical manifestation
Meningioencephalitis 157 (56.3) 242 (55.3)
Encephalitis 58 (20.7) 78 (17.8)
Meningitis 48 (17.2) 87 (19.9)
Uncomplicated fever 14 (5.0) 18 (4.4)
Other 2 (0.7) 3 (0.7)
Unknown 3 8
Death 5 (1.86) 6 (1.43)
Unknown* 13 16
*Unknown, represents the number of confirmed and probable cases for which
the case outcome was not reported.
doi:10.1371/journal.pone.0006145.t002
Table 3. Non-Imported Probable and Confirmed Cases and
Incidence Risk* of La Crosse Virus Infections for Children 15
years and Younger in the eastern United States, 2003 to 2007,
by Region.
Northern Region
??
Month Incidence Risk
June 2.9
July 1.8
August 1.8
September 4.0
October 3.7
Southern Region
{
Month Incidence Risk
March 2.4
April 16.7
May 20.7
June 10.7
July 8.9
August 9.8
September 12.6
October 8.5
November 2.0
*Incidence risk was calculated by region and month using the both probable
and confirmed cases of La Crosse virus infections and presented as the number
of cases per 100,000 persons in children 15 years and younger.
??Illinois, Iowa, Indiana, Michigan, Minnesota, Ohio, and Wisconsin.
{Alabama, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South
Carolina, Tennessee, Virginia, and West Virginia.
doi:10.1371/journal.pone.0006145.t003
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efforts.
The majority of cases reported occurred in the summer months
(June, July, and August) in agreement with previous studies
[2,17,18], with a significantly higher incidence risk occurring in
southern states during the months of June, July, August, and
September. This is likely due to the transmission cycle of LACV,
which involves both horizontal and vertical transmission. The
burden of infected mosquitoes would continue to increase into the
summer months as each successive generation of mosquitoes fed
upon viremic amplification hosts, followed by increased trans-
ovarial transmission of the virus to their progeny. The highest risk
of infection would thus occur during the height of this
amplification process when the highest burden of infected
mosquitoes would be reached. The height of this viral amplifica-
tion coincides with the summer months when humans are most
apt to spend the most time outdoors, thus putting themselves at an
increased risk for coming into contact with infectious mosquitoes.
Temperature may play a role in the higher incidence risk in
southern region of the United States. Given that transovarial
transmission following one gonotrophic cycle is likely rare in nature
[6], orally infected Ae. triseriatus, likely need to complete at least two
gonotrophiccyclestotransovariallytransmittheLACV totheireggs
[37]. As only a small percentage of Ae. triseriatus may survive to
complete their second gonotrophic cycle in nature [37], an increase
in the ambient temperature would increase the number of
gonotrophic cycles possible in lifespan of a vector. Additionally,
higher temperatures would have the added effect of increasing viral
dissemination, titers, and transmission in vectors [38,39]. Warmer
temperatures, which are traditionally present for longer periods of
time in the southern United States could therefore be playing a
substantial role in increasing overall vectorial capacity.
Previous studies have shown that over 90 percent of reported
cases occur in children 15 years and younger [16], with
approximately 64 percent of these cases occurring in males [16].
Our study confirms these findings with roughly 83 percent of
confirmed cases occurring in children 15 years and younger and
64.9 percent of these cases occurring in males. Clinical studies
have demonstrated similar findings [13,40,41]. The tendency for
children to develop severe LACV infections may be due to a
variety of factors including differences in the pediatric and adult
immune system, virus dose, and/or the longer time children may
spend outdoors, though such risk factors are not well understood.
It has been hypothesized elsewhere that the higher incidence risk
in males may be due to the greater time boys spend outdoors, thus
increasing their risk of contact with infectious vectors [21,42].
Of the 426 reported probable and confirmed LACV infections
during our study period, the Appalachian region including West
Virginia, North Carolina, Ohio, and Tennessee reported 22.2
percent, 20.8 percent, 18.5 percent and 22.2 percent of reported
cases, respectively, and accounted for 74.5 percent of all cases
during the study period. A previous study from 1964–1981,
reported 1348 cases in the United States of which 88.8 percent
came from Ohio, Wisconsin, Minnesota, Illinois, and Iowa [16],
while only 2 percent came from North Carolina, Tennessee, and
West Virginia. Though our results encompass only a five-year
period, the higher incidence risk in these states may indicate a shift
in LACV infections from the upper Midwest to the Appalachian
region of the United States [12,13,14]. The reason for this shift is
unclear, but could be due to a number of factors including changes
in diagnosis, reporting, prevention strategies, as well as changes in
the epidemiology of the disease.
Though our finding of an mean incidence risk of 30.2 per
100,000 persons for children 15 years and younger in probable
and confirmed cases combined for eastern United States was
similar to previous reports of an incidence risk of 20 to 30 per
100,000 persons in the same age group [43,44], our mean
incidence risk in the significantly high spatial clusters was
numerically higher, 54.6 per 100,000 persons, then the incidence
risk previously reported for the same age group [43,44]. In the
individual counties reporting cases of LACV infections we found
the incidence risk in children 15 years and younger ranging from
0.16 to 165.4 per 100,000 persons using only confirmed cases, and
from 0.2 to 228.7 per 100,000 persons using both confirmed and
probable cases combined. These results indicate the wide variation
that occurs due to the focal nature of the virus within counties
reporting LACV infections, and highlights the need to report the
range of incidence risk, rather than reporting only the mean
incidence risk which may not provide an accurate assessment of
risk within these focal areas.
Figure 1. Distribution of unsmoothed and smoothed incidence risk in children 15 years and younger. The map on the left represents
the distribution of a) unsmoothed risk, and on the right b) smoothed risk of La Crosse virus infections at the county level for the eastern United States.
doi:10.1371/journal.pone.0006145.g001
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States by Lindsey et al. [45], analyzed five years of WNV infection
data reported to the ArboNET surveillance system. The authors
found a state level incidence risk for WNV infections ranging from
0.2 to 32.2 per 100,000 for the total population and a county level
incidence risk ranging from 0.1 to 241.2 per 100,000 for the total
population. Though the range of our state level incidence risk for
LACV infections in the at-risk population was higher, ranging
from 0.7 to 56.4 per 100,000 in children 15 years and younger,
our county level incidence risk for LACV infections was similar to
their findings, 0.7 to 228.7 per 100,000 persons in children 15
years and younger. These results indicate that the incidence risk of
LACV infections are similar to that of WNV infections.
When the results from our analysis of those counties in the study
area reporting both probable and confirmed cases of LACV
infections are compared with pediatric WNV infection cases
reported in Cuyahoga County, Ohio, in 2002 [15], LACV
infections had a higher incidence risk in the pediatric population
than that estimated for WNV infections, 7.2 per 100,000 persons
in children 15 years and younger to 1.4 per 100,000 persons in
children 5 to 17 years of age, respectively. In those counties
reporting probable and confirmed cases of LACV infections in the
population .16 years and older we found an incidence of 0.34 per
100,000 persons, while in Cuyahoga County, Ohio, LeBeaud et al.
[15] estimated the incidence risk in the population $18 years and
older to be 14.3 per 100,000 persons. It is clear that the severe
infections caused by these two arboviruses present in the pediatric
and adult populations differently, with severe LACV infections
having a much higher incidence risk in children than adults, the
opposite of that of WNV infections. The cause(s) for the differences
Figure 2. Spatial patterns of disease risk in children 15 years and younger. This map shows the significant clustering of La Crosse virus
infections at the county level detected by the Moran’s I Local Indicators of Spatial Autocorrelation (LISA) for the eastern United States. Four types of
spatial autocorrelation are observed using the LISA statistic (High-High, Low-Low, High-Low, and Low-High). Positive spatial autocorrelation is
represented by High-High and Low-Low, and negative spatial correlation by High-Low and Low-High. Positive spatial autocorrelation (i.e. an
association of areas of similar values) were represented as either High-High (i.e. a high risk in an area surrounded by similarly high values in
neighboring areas) or Low-Low (i.e. a low risk in an area surrounded by similarly low values in neighboring areas). Negative spatial autocorrelation (i.e.
an association of areas of dissimilar values) was represented as either High-Low (i.e. a high rate in an area surrounded by low values in neighboring
areas) or Low-High (i.e. a low rate in an area surrounded by high values in neighboring areas).
doi:10.1371/journal.pone.0006145.g002
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pediatric and adult populations remains unknown, but warrants
further investigation.
From the results of LACV serosurveys conducted in endemic
regions it is clear that the risk of asymptomatic infections is much
higher than symptomatic infections, with estimates of asymptom-
atic infections to clinical infections in pediatric populations ranging
from 2:1 to 1500:1 [19,20,21]. The incidence risk of LACV
infections are therefore likely much higher, as only the most severe
cases typically present for medical care and hence get reported.
The results from these studies suggest that there are most likely
several hundred thousand infections per year in the United States
[19,20,21], but our findings suggest that there are many more
cases than previously estimated. The spatial distribution (Figure 1)
reaffirms the focal nature of these infections, and identifies the
areas with the highest risk.
The use of probable and confirmed cases combined increased
overall cluster detection from 47 to 54 counties. The significant
high risk clusters detected should be targeted for future studies and
for interventions by public health officials. Reporting the mean
incidence risk at the state or county level may lead to a distorted
picture of the spatial patterns of LACV infections and thus
decrease the perception of risk. Future reporting should include
the range of incidence risk occurring in those counties reporting
cases. This will minimize misperceptions of risk, as the use of
incidence risk continues to remain the most used tool to identify
high risk areas for education, prevention, and intervention.
Though LACV infections are typically reported as LAC
encephalitis there appear to be four distinct clinical syndromes,
as well as asymptomatic infections [2,13,40,41,46], These include
the most severe LAC encephalitis, LAC meningioencephalitis,
LAC meningitis, and LAC fever. It is difficult to assess the true
incidence of these syndromes since they have often been
collectively reported as LAC encephalitis in previous reports/
studies [40,41,47]. Accurate reporting of the patients’ clinical
syndrome is necessary to determine and monitor the future rates of
disease presentation.
Our study found a case fatality rate of 1.9 percent in confirmed
cases, with all of the deaths occurring in patients presenting
encephalitis. The majority of deaths were in children 15 years and
younger. This finding is much higher than the case fatality rate of
0.3 percent reported in a previous study of LACV infections in the
United States [16]. The reason for the higher case fatality rate is
unclear, but many factors should be considered including variation
in the virulence of the LACV strain(s) circulating in this region of
the United States [48]. These findings suggest that LACV
infections may be more severe than sometimes reported in
medical literature. Three deaths (probable and confirmed cases
combined) occurred in two of the four highly significant clusters of
probable and confirmed cases of LACV infections in West
Virginia and Tennessee.
Our study has some limitations. Probable and confirmed cases
were reported through a passive surveillance system, which
inherently suffers under-reporting. Not withstanding this limitation
we feel that the majority of cases progressing to severe illness were
diagnosed and reported to public health officials. Using only
confirmed cases as well as probable and confirmed cases
combined, we were able to demonstrate similar high incidence
risk and case fatality rates. We were also able to show similar
patterns in disease clustering. Clinical data was reported from
multiple state health departments to the Centers for Disease
Control and Prevention, which did not allow for the verification of
laboratory results and the diagnosis of the specific clinical
presentation for each patient. We feel that this is a small limitation
and that the majority of cases reported have been correctly
separated into the four manifestations of severe LACV infections
by clinicians.
One drawback to using the LISA is the issue of multiple
comparisons which increases type I error rates. We didn’t make an
attempt to adjust for this because some authors have suggested
that any adjustments made to reduce the type I errors would
increase type II errors [30,49], in turn reducing the test’s power to
detect truly significant clusters.
Our findings of a high incidence risk within significantly high
spatial clusters and high case-fatality rate indicate a much higher
burden of disease than previously reported, and demonstrate that
LACV infections are much more common than previously
reported. We have demonstrated the usefulness of these spatial
statistical techniques to detect hot-spots of infections, thus allowing
for targeted interventions by public health officials while raising
awareness among health care providers of geographic areas at the
highest risk of disease.
Our results will allow focused national serological studies, form
the basis for the development of predictive models of virus
transmission, provide a methodology for the use spatial analyses at
a national level for other infectious diseases, and demonstrate the
need for the reporting of arboviral and other disease cases at
smaller geographic scales.
Acknowledgments
We would like to thank the Arboviral Diseases Branch of the Centers for
Disease Control and Prevention for releasing the surveillance data to our
group, and their comments on the draft manuscript. We would also like to
offer our sincere thanks to the staff of all the many local and state health
departments who collected La Crosse virus infection case data and
submitted them to the Centers for Disease Control and Prevention.
Without their contributions this work would not have been possible.
Author Contributions
Conceived and designed the experiments: ADH AO. Performed the
experiments: ADH AO. Analyzed the data: ADH AO. Wrote the paper:
ADH AO.
References
1. Thompson WH, Kalfayan B, Anslow RO (1965) Isolation of California
encephalitis group virus from a fatal human illness. Am J Epidemiol 81:
245–253.
2. Calisher CH (1994) Medically important arboviruses of the United States and
Canada. Clin Microbiol Rev 7: 89–116.
3. Tsai TF (1991) Arboviral infections in the United States. Infect Dis Clin North
Am 5: 73–102.
4. Watts DM, Morris CD, Wright RE, DeFoliart GR, Hanson RP (1972)
Transmission of La Crosse virus (California encephalitis group) by the mosquito
Aedes triseriatus. J Med Entomol 9: 125–127.
5. Beaty BJ, Calisher CH (1991) Bunyaviridae - Natural History. Curr Top Micro
Imm 169: 27–28.
6. Watts DM, Pantuwatana S, DeFoliart GR, Yuill TM, Thompson WH (1973)
Transovarial transmission of La Crosse virus (California encephalitis group) in
the mosquito, Aedes triseriatus. Science 182: 1140–1141.
7. Watts DM, Thompson WH, Yuill TM, DeFoliart GR, Hanson RP (1974)
Overwintering of La Crosse virus in Aedes triseriatus. Am J Trop Med Hyg 23:
694–700.
8. Thompson WH, Beaty BJ (1977) Venereal transmission of La Crosse (California
encephalitis) arbovirus in Aedes triseriatus mosquitoes. Science 196: 530–531.
La Crosse Virus Infections
PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e61459. Moulton DW, Thompson WH (1971) California group virus infections in small,
forest-dwelling mammals of Wisconsin. Some ecological considerations.
Am J Trop Med Hyg 20: 474–482.
10. Ksiazek TG, Yuill TM (1977) Viremia and antibody response to La Crosse virus
in sentinel gray squirrels (Sciuris carolinensis) and chipmunks (Tamias striatus).
Am J Trop Med Hyg 26: 815–821.
11. Grimstad P (1988) California group virus disease. In: The arboviruses: epidemiology
and ecology Vol II, Monath TP, ed. Boca Raton, FL: CRC Press. pp 99–136.
12. Jones TF, Craig AS, Nasci RS, Patterson LE, Erwin PC, et al. (1999) Newly
recognized focus of La Crosse encephalitis in Tennessee. Clin Infect Dis 28:
93–97.
13. McJunkin JE, de los Reyes EC, Irazuzta JE, Caceres MJ, Khan RR, et al. (2001)
La Crosse encephalitis in children. N Engl J Med 344: 801–807.
14. Nasci RS, Moore CG, Biggerstaff BJ, Panella NA, Liu HQ, et al. (2000) La
Crosse encephalitis virus habitat associations in Nicholas County, West Virginia.
J Med Entomol 37: 559–570.
15. LaBeaud AD, Lisgaris MV, King CH, Mandalakas AM (2006) Pediatric West
Nile virus infection: neurologic disease presentations during the 2002 epidemic
in Cuyahoga County, Ohio. Pediatr Infect Dis J 25: 751–753.
16. Kappus KD, Monath TP, Kaminski RM, Calisher CH (1983) Reported
encephalitis associated with California serogroup virus infections in the United
States, 1963–1981. Prog Clin Biol Res 123: 31–41.
17. McJunkin JE, Khan RR, Tsai TF (1998) California-La Crosse encephalitis.
Infect Dis Clin North Am 12: 83–93.
18. Rust RS, Thompson WH, Matthews CG, Beaty BJ, Chun RW (1999) La Crosse
and other forms of California encephalitis. J Child Neurol 14: 1–14.
19. Grimstad PR, Barrett CL, Humphrey RL, Sinsko MJ (1984) Serologic evidence
for widespread infection with La Crosse and St. Louis encephalitis viruses in the
Indiana human population. Am J Epidemiol 119: 913–930.
20. Kappus KD, Calisher CH, Baron RC, Davenport J, Francy DB, et al. (1982) La
Crosse virus infection and disease in western North Carolina. Am J Trop Med
Hyg 31: 556–560.
21. Monath TP, Nuckolls JG, Berall, Bauer H, Chappell WA, et al. (1970) Studies
on California encephalitis in Minnesota. Am J Epidemiol 92: 40–50.
22. Darsie RF, Ward RA (1981) Identification and geographic distribution of the
mosquitoes of North America, north of Mexico. Mosq Syst Suppl 1: 1–313.
23. Reimann CA, Hayes EB, DiGuiseppi C, Hoffman R, Lehmann JA, et al. (2008)
Epidemiology of neuroinvasive arboviral disease in the United States, 1999–
2007. Am J Trop Med Hyg 79: 974–979.
24. CDC (2004) Neuroinvasive and non-neuroinvasive domestic arboviral diseases:
2004 case definition. In: National Center for Public Health Informatics (NCPHI)
D, NNDSS, editor. 2004 ed. Atlanta, Georgia: Centers for Disease Control.
25. Gabitzsch ES, Blair CD, Beaty BJ (2006) Effect of La Crosse virus infection on
insemination rates in female Aedes triseriatus (Diptera: Culicidae). J Med Entomol
43: 850–852.
26. US Census Bureau, 2000 Decennial Census, Summary File 1.
27. US Census Bureau, Cartographic Boundary File Web Site.
28. STATA (2007) Intercooled STATA Version 10.0 for Macintosh. College
Station, Texas, USA: STATA Corporation.
29. Clayton D, Bernardinelli L (1997) Bayesian methods for mapping disease risk;
In: Elliott P, Cuzick J, English D, Stern R, eds. Oxford: Oxford University Press.
30. Odoi A, Martin SW, Michel P, Holt J, Middleton D, et al. (2003) Geographical
and temporal distribution of human giardiasis in Ontario, Canada. Int J Health
Geogr 2: 5.
31. Bernardinelli L, Montomoli C (1992) Empirical Bayes versus fully Bayesian
analysis of geographical variation in disease risk. Stat Med 11: 983–1007.
32. Bithell JF (2000) A classification of disease mapping methods. Stat Med 19:
2203–2215.
33. Moran PA (1950) Notes on continuous stochastic phenomena. Biometrika 37:
17–23.
34. Anselin L (1995) Local indicators of spatial association - LISA. Geogr anal 27:
93–115.
35. Anselin L (2003) GeoDa Version 0.95i. Spatial Analysis Lab University of
Illinois.
36. ESRI (2006) ArcView GIS Version 9.2. RedlandsCalifornia: Environmental
Systems Research Institute, Inc.
37. Miller BR, DeFoliart GR, Yuill TM (1979) Aedes triseriatus and La Crosse virus:
lack of infection in eggs of the first ovarian cycle following oral infection of
females. Am J Trop Med Hyg 28: 897–901.
38. Bates M, Roca-Garcia M (1946) The development of the virus of yellow fever in
Haemagogus mosquitoes. Am J Trop Med Hyg 26: 585–605.
39. Kilpatrick AM, Meola MA, Moudy RM, Kramer LD (2008) Temperature, viral
genetics, and the transmission of West Nile virus by Culex pipiens mosquitoes.
PLoS Pathog 4: e1000092.
40. Chun RW, Thompson WH, Grabow JD, Matthews CG (1968) California
arbovirus encephalitis in children. Neurology 18: 369–375.
41. Balfour HH Jr, Siem RA, Bauer H, Quie PG (1973) California arbovirus (La
Crosse) infections. I. Clinical and laboratory findings in 66 children with
meningoencephalitis. Pediatrics 52: 680–691.
42. Thompson WH, Evans AS (1965) California encephalitis virus studies in
Wisconsin. Am J Epidemiol 81: 230–244.
43. La Crosse encephalitis in West Virginia. MMWR Morb Mortal Wkly Rep 37:
79–82.
44. Hurwitz ES, Schell W, Nelson D, Washburn J, LaVenture M (1983) Surveillance
for California encephalitis group virus illness in Wisconsin and Minnesota, 1978.
Am J Trop Med Hyg 32: 595–601.
45. Lindsey NP, Kuhn S, Campbell GL, Hayes EB (2008) West Nile virus
neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne
Zoonotic Dis 8: 35–39.
46. Gundersen CB, Brown KL (1983) Clinical aspects of La Crosse encephalitis:
preliminary report. Prog Clin Biol Res 123: 169–177.
47. Hilty MD, Haynes RE, Azimi PH, Cramblett HG (1972) California encephalitis
in children. Am J Dis Child 124: 530–533.
48. Huang C, Thompson WH, Karabatsos N, Grady L, Campbell WP (1997)
Evidence that fatal human infections with La Crosse virus may be associated
with a narrow range of genotypes. Virus Res 48: 143–148.
49. Rothman KJ (1990) No adjustments are needed for multiple comparisons.
Epidemiology 1: 43–46.
La Crosse Virus Infections
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6145